Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $447.10 to $456.28
• 50-Day Range: $298.58 to $448.91
• 52-Week Range: $205.87 to $456.28
• Volume: 776,827 shs
• Average Volume: 950,016 shs
• Market Capitalization: $59.70 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $405.33
• Consensus Rating: Moderate Buy

Alnylam Pharmaceuticals Stock Analysis - MarketRank™

Alnylam Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 337th out of 1,876 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 22 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alnylam Pharmaceuticals has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($1.70) to $0.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alnylam Pharmaceuticals is -183.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alnylam Pharmaceuticals is -183.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alnylam Pharmaceuticals has a P/B Ratio of 871.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.51% of the float of Alnylam Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alnylam Pharmaceuticals has recently decreased by 4.14%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alnylam Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Alnylam Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.52

Percentage of Shares Shorted

2.51% of the float of Alnylam Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alnylam Pharmaceuticals has recently decreased by 4.14%, indicating that investor sentiment is improving.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.24

News Sentiment

Alnylam Pharmaceuticals has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for Alnylam Pharmaceuticals this week, compared to 20 articles on an average week.

Search Interest

15 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

9 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,265,349.00 in company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Alnylam Pharmaceuticals is held by insiders.

Percentage Held by Institutions

92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALNY Stock Analysis - Frequently Asked Questions

How have ALNY shares performed this year?

Alnylam Pharmaceuticals' stock was trading at $235.31 at the beginning of the year. Since then, ALNY stock has increased by 92.7% and is now trading at $453.4250.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Thursday, July, 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals's revenue was up 17.3% compared to the same quarter last year.
Read the conference call transcript.

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' top institutional investors include Vanguard Group Inc. (10.14%), Dodge & Cox (2.44%), Geode Capital Management LLC (1.83%) and Orbis Allan Gray Ltd (1.62%). Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Tolga Tanguler, Kevin Joseph Fitzgerald, Pushkal Garg, Amy W Schulman, Dennis A Ausiello, David E I Pyott, Phillip A Sharp and Indrani Lall Franchini.
View institutional ownership trends.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 8/18/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALNY
• CIK: 1178670
• Web: www.alnylam.com
• Phone: (617) 551-8200
• Fax: 617-551-8101
• Employees: 2,230
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Alnylam Pharmaceuticals: $405.33
• High Price Target: $570.00
• Low Price Target: $220.00
• Potential Upside/Downside: -9.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$278.16 million
• Net Margins: -12.96%
• Pretax Margin: -15.42%
• Return on Equity: -273.52%
• Return on Assets: -7.39%

Debt

• Debt-to-Equity Ratio: 4.10
• Current Ratio: 2.80
• Quick Ratio: 2.75

Sales & Book Value

• Annual Sales: $2.25 billion
• Price / Sales: 26.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 863.29

Miscellaneous

• Outstanding Shares: 131,080,000
• Free Float: 129,506,000
• Market Cap: $58.84 billion
• Optionable: Optionable
• Beta: 0.25